Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cochlear Limited	
ABN	96 002 618 073	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Michael Smith
Date of last notice	5 November 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	Change 1: 15 August 2016 Change 2: 15 August 2016 Change 3: 12 August 2016 Change 4: 11 August 2016 Change 5: 16 August 2016
No. of securities held prior to change	 (a) 18,288 shares (b) 99,414 LTI Options (c) 11,837 LTI Performance Rights (d) 3,226 STI Performance Rights

⁺ See chapter 19 for defined terms.

ully paid ordinary shares in Cochlear imited ("shares") ong term incentive options subject to erformance hurdles and vesting meframes ("LTI Options") ong term incentive share rights subject o performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI Performance Rights") orge 1: 12,098 shares age 2: 2,587 shares age 3: 1,199 shares
erformance hurdles and vesting meframes ("LTI Options") ong term incentive share rights subject o performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI Performance Rights") oge 1: 12,098 shares oge 2: 2,587 shares
p performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI verformance Rights") nge 1: 12,098 shares nge 2: 2,587 shares
ubject to vesting timeframes ("STI Performance Rights") ge 1: 12,098 shares ge 2: 2,587 shares
ge 2: 2,587 shares
ge 4: 10,788 shares
ge 5: 5,384 shares
ge 1: 12,098 LTI Options exercised at 3 per share
ge 2: 2,587 LTI Performance Rights at tercise price
ge 3: 1,199 STI Performance Rights at tercise price
ge 4: \$135.3634
ge 5: \$138.3519
n

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Change 1, Change 2 and Change 3: Mr Smith acquired a total of 15,884 shares
	through the exercise of 12,098 LTI Options, 2,587 LTI Performance Rights, and 1,199 STI Performance Rights under the Cochlear Executive Incentive Plan. Each LTI Option,
	LTI Performance Right and STI Performance Right entitles Mr Smith to subscribe for, be allocated or receive the transfer of, one fully paid ordinary share in Cochlear Limited.
	Change 4 and Change 5:
	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Change 6:
	Mr Smith previously entered into a financing arrangement in relation to fully paid ordinary shares in Cochlear Limited. The transaction included put options exercisable in August and October 2016. The financing arrangement has been renewed in respect of 18,000 shares. As part of this financing arrangement, Mr Smith has acquired put options with the financier for the 18,000 shares which expire in August 2017.
Nature of interest	Direct
Name of registered holder (if issued securities)	Christopher Michael Smith
Date of change	Change 6: 11 August 2016
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	18,288 shares

⁺ See chapter 19 for defined terms.

Interest acquired	Refer to "Detail of contract"
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	A premium is payable to the financier for the transaction.
Interest after change	Financing arrangements relating to 18,000 shares, including put options.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cochlear Limited	
ABN	96 002 618 073	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Michael Smith
Date of last notice	5 November 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	Change 1: 15 August 2016 Change 2: 15 August 2016 Change 3: 12 August 2016 Change 4: 11 August 2016 Change 5: 16 August 2016
No. of securities held prior to change	 (a) 18,288 shares (b) 99,414 LTI Options (c) 11,837 LTI Performance Rights (d) 3,226 STI Performance Rights

⁺ See chapter 19 for defined terms.

ully paid ordinary shares in Cochlear imited ("shares") ong term incentive options subject to erformance hurdles and vesting meframes ("LTI Options") ong term incentive share rights subject o performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI Performance Rights") orge 1: 12,098 shares age 2: 2,587 shares age 3: 1,199 shares
erformance hurdles and vesting meframes ("LTI Options") ong term incentive share rights subject o performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI Performance Rights") oge 1: 12,098 shares oge 2: 2,587 shares
p performance hurdles and vesting meframes ("LTI Performance Rights") hort term incentive share rights ubject to vesting timeframes ("STI verformance Rights") nge 1: 12,098 shares nge 2: 2,587 shares
ubject to vesting timeframes ("STI Performance Rights") ge 1: 12,098 shares ge 2: 2,587 shares
ge 2: 2,587 shares
ge 4: 10,788 shares
ge 5: 5,384 shares
ge 1: 12,098 LTI Options exercised at 3 per share
ge 2: 2,587 LTI Performance Rights at tercise price
ge 3: 1,199 STI Performance Rights at tercise price
ge 4: \$135.3634
ge 5: \$138.3519
n

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Change 1, Change 2 and Change 3: Mr Smith acquired a total of 15,884 shares
	through the exercise of 12,098 LTI Options, 2,587 LTI Performance Rights, and 1,199 STI Performance Rights under the Cochlear Executive Incentive Plan. Each LTI Option,
	LTI Performance Right and STI Performance Right entitles Mr Smith to subscribe for, be allocated or receive the transfer of, one fully paid ordinary share in Cochlear Limited.
	Change 4 and Change 5:
	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Change 6:
	Mr Smith previously entered into a financing arrangement in relation to fully paid ordinary shares in Cochlear Limited. The transaction included put options exercisable in August and October 2016. The financing arrangement has been renewed in respect of 18,000 shares. As part of this financing arrangement, Mr Smith has acquired put options with the financier for the 18,000 shares which expire in August 2017.
Nature of interest	Direct
Name of registered holder (if issued securities)	Christopher Michael Smith
Date of change	Change 6: 11 August 2016
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	18,288 shares

⁺ See chapter 19 for defined terms.

Interest acquired	Refer to "Detail of contract"
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	A premium is payable to the financier for the transaction.
Interest after change	Financing arrangements relating to 18,000 shares, including put options.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	Νο
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.